Summary
Project Summary/Abstract Type 1 diabetes (T1D), which is characterized by T cell-mediated destruction of insulin-producing pancreatic beta cells, has a relatively well-defined genetic architecture that explains about 50% of inter-individual differences in disease risk. However, translating the genetic architecture into novel disease insights and therapies has lagged behind because its molecular and cellular mechanisms are incompletely understood. Studies have established a strong impact of T1D genetics on T cells, which supports the development of the only FDA-approved drug for delaying T1D-on
